A bacterial infection is not just an unpleasant experience — it can also be a major health problem. Some bacteria develop resistance to otherwise effective treatment with antibiotics. Therefore, researchers are trying to develop new types of antibiotics that can fight the bacteria, and at the same time trying to make the current treatment with antibiotics more effective.

Researchers are now getting closer to this goal with a type of bacteria called Pseudomonas aeruginosa, which is notorious for infecting patients with the lung disease cystic fibrosis. In a new study, researchers found that the bacteria send out warning signals to their conspecifics when attacked by antibiotics or the viruses called bacteriophages which kill bacteria.

“We can see in the laboratory that the bacteria simply swim around the ‘dangerous area’ with antibiotics or bacteriophages. When they receive the warning signal from their conspecifics, you can see in the microscope that they are moving in a neat circle around. It is a smart survival mechanism for the bacteria. If it turns out that the bacteria use the same evasive manoeuvre when infecting humans, it may help explain why some bacterial infections cannot be effectively treated with antibiotics,” says researcher Nina Molin Høyland-Kroghsbo, Assistant Professor at the Department of Veterinary and Animal Sciences and part of the research talent programme UCPH-Forward.

One United Organism

In the study, which is a collaboration between the University of Copenhagen and the University of California Irvine, researchers have studied the growth and distribution of bacteria in petri dishes. Here, they have created environments that resemble the surface of the mucous membranes where an infection can occur — as is the case with the lungs of a person with cystic fibrosis.

In this environment, researchers can see both how bacteria usually behave and how they behave when they are affected by antibiotics and bacteriophages.

“It is quite fascinating for us to see how the bacteria communicate and change behaviour in order for the entire bacterial population to survive. You can almost say that they act as one united organism,” says Nina Molin Høyland-Kroghsbo.

Possibility of Blocking

The Pseudomonas aeruginosa bacteria are such a big problem that they are found in the top category ‘critical’ in the World Health Organization’s list of bacteria, where new types of antibiotics are most urgently needed. Therefore, the researchers are excited to make new discoveries about the ways in which this type of bacteria behaves and survives.

“Infections with this type of bacteria are a major problem worldwide with many hospitalisations and deaths. That is why we are really pleased to be able to contribute new knowledge that can potentially be used to fight these bacteria,” says Nina Molin Høyland-Kroghsbo.

However, she emphasises that it will still take a long time for the new knowledge to result in better treatment. The next step is to research how to affect the bacteria’s communication and warning signals.

“This clears the way for the use of drugs in an attempt to prevent that the warning signal is sent out in the first place. Alternatively, you could design substances that may block the signal from being received by the other bacteria, and this could potentially make treatment with antibiotics or bacteriophage viruses more effective,” concludes Nina Molin Høyland-Kroghsbo.

The study is supported by the Lundbeck Foundation.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Before you post, please prove you are sentient.

what is 8 + 6?

Explore More

Cheap, quick test identifies pneumonia patients at risk of respiratory failure or sepsis

Spanish researchers in Valencia have identified specific fragments of genetic material that play a role in the development of respiratory failure and sepsis in pneumonia patients. Presenting the research at

Synthetic molecules can ‘ferry’ mucus-clearing ions blocked by cystic fibrosis

A University at Buffalo-led research team has developed molecules that could help unclog thick, sticky mucus from the lungs of people suffering from cystic fibrosis. The chronic disease is caused

Landmark study involving babies in Ireland supports use of Cystic Fibrosis drug in infants from four weeks of age

A Cystic Fibrosis drug targeting the basic defect that causes the condition has been shown to be safe and effective in newborns aged four weeks and above, new research involving